JESSICA LYNN LEVATINO M.D.
Prescription History 1285924944
Family Medicine in Stanford, CA

NPI Status: Active since April 14, 2011

Contact Information

300 PASTEUR DR
STANFORD, CA
ZIP 94305
Phone: (650) 723-4000

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for JESSICA LYNN LEVATINO M.D., an active Family Medicine specialist practicing in Stanford, CA. Our medical registry currently tracks 5 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 77 documented patient claims. Among these therapy options, the most frequently utilized medication is Atorvastatin Calcium, which accounts for 20 claims alone.

Medication Index


Atorvastatin Calcium

Generic Formulation: Atorvastatin CalciumSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 20
30-Day Fills 54.0
Days Supply 1,620
CA State Average Benchmarks
Peer Average Claims194.0
Peer Average 30-Day Fills503.5
Peer Average Days Supply14,987
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 89.7% less volume than the regional standard for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $325.81 across this reporting matrix range.

Provider Avg Cost Per Claim

$16.29

State Avg Cost Per Claim

$14.16

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pyrrole and heptanoic acid derivative, HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITOR (statin), and ANTICHOLESTEREMIC AGENT that is used to reduce serum levels of LDL-CHOLESTEROL; APOLIPOPROTEIN B; and TRIGLYCERIDES. It is used to increase serum levels of HDL-CHOLESTEROL in the treatment of HYPERLIPIDEMIAS, and for the prevention of CARDIOVASCULAR DISEASES in patients with multiple risk factors.

Therapeutic Applications

Atorvastatin is used along with a proper diet to help lower bad cholesterol and fats (such as LDL, triglycerides) and raise good cholesterol (HDL) in the blood. It belongs to a group of drugs known as statins. It works by reducing the amount of cholesterol made by the liver. Lowering bad cholesterol and triglycerides and raising good cholesterol decreases the risk of heart disease and helps prevent strokes and heart attacks. In addition to eating a proper diet (such as a low-cholesterol/low-fat diet), other lifestyle changes that may help this medication work better include exercising, losing weight if overweight, and stopping smoking. Consult your doctor for more details.

Ciprofloxacin Hcl

Generic Formulation: Ciprofloxacin HclSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 85
CA State Average Benchmarks
Peer Average Claims29.0
Peer Average 30-Day Fills29.9
Peer Average Days Supply258
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 55.2% less volume than the regional standard for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $83.06 across this reporting matrix range.

Provider Avg Cost Per Claim

$6.39

State Avg Cost Per Claim

$7.51

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A broad-spectrum antimicrobial carboxyfluoroquinoline.

Therapeutic Applications

This medication is used to treat eye infections. Ciprofloxacin belongs to a class of drugs called quinolone antibiotics. It works by stopping the growth of bacteria. This medication treats only bacterial eye infections. It will not work for other types of eye infections. Unnecessary use or overuse of any antibiotic can lead to its decreased effectiveness.

Losartan Potassium

Generic Formulation: Losartan PotassiumSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 12
30-Day Fills 26.0
Days Supply 780
CA State Average Benchmarks
Peer Average Claims116.0
Peer Average 30-Day Fills302.4
Peer Average Days Supply9,023
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 89.7% less volume than the regional standard for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $74.84 across this reporting matrix range.

Provider Avg Cost Per Claim

$6.24

State Avg Cost Per Claim

$13.35

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.

Therapeutic Applications

Losartan is used to treat high blood pressure (hypertension) and to help protect the kidneys from damage due to diabetes. It is also used to lower the risk of strokes in patients with high blood pressure and an enlarged heart. Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. Losartan belongs to a class of drugs called angiotensin receptor blockers (ARBs). It works by relaxing blood vessels so that blood can flow more easily.

Paxlovid (Eua)

Generic Formulation: Nirmatrelvir/RitonavirSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 17
30-Day Fills 17.0
Days Supply 85
CA State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills24.7
Peer Average Days Supply125
Conservative Utilization

This provider writes prescriptions for this formulation 29.2% less frequently than the standard regional baseline metric for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $179.00 across this reporting matrix range.

Provider Avg Cost Per Claim

$10.53

State Avg Cost Per Claim

$11.70

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

The combination of nirmatrelvir tablets and ritonavir tablets is a product that the FDA is allowing to be given for emergency use to treat COVID-19. The product is also approved to be used in Canada to treat COVID-19. It is used by people who have recently tested positive for coronavirus, have had mild to moderate symptoms for no more than 5 days and are not hospitalized. To receive this product you must also be at high risk for COVID-19 complications due to older age, obesity, or ongoing medical conditions (such as lung or heart disease or diabetes, among others). Talk to your doctor about the risks and benefits of treatment with nirmatrelvir and ritonavir. Nirmatrelvir is a SARS-CoV-2 main protease inhibitor. It works by preventing the growth of the virus that causes COVID-19. Ritonavir increases (boosts) the levels of nirmatrelvir. This helps nirmatrelvir work better. More information about nirmatrelvir and ritonavir is available from the FDA Fact Sheet for Patients, Parents, and Caregivers for Emergency Use and from the Health Canada Patient Medication Information sheet. There is limited information about how safe and effective the combination of nirmatrelvir and ritonavir is for treating COVID-19. Study results show that nirmatrelvir and ritonavir may help people who have recently tested positive for coronavirus stay out of the hospital. This product is not for use by people who are hospitalized due to COVID-19. The information in this document reflects emerging data, which is evolving and subject to reassessment. Users should be aware of these considerations in their review of nirmatrelvir and ritonavir, and it is always the responsibility of treating practitioners to exercise independent judgement in making care decisions.

Valacyclovir

Generic Formulation: Valacyclovir HclSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 15
30-Day Fills 17.0
Days Supply 511
CA State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills32.7
Peer Average Days Supply745
Conservative Utilization

This provider writes prescriptions for this formulation 28.6% less frequently than the standard regional baseline metric for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $403.91 across this reporting matrix range.

Provider Avg Cost Per Claim

$26.93

State Avg Cost Per Claim

$52.83

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A prodrug of acyclovir that is used in the treatment of HERPES ZOSTER and HERPES SIMPLEX VIRUS INFECTION of the skin and mucous membranes, including GENITAL HERPES.

Therapeutic Applications

Valacyclovir is used to treat infections caused by certain types of viruses. In children, it is used to treat cold sores around the mouth (caused by herpes simplex) and chickenpox (caused by varicella zoster). In adults, it is used to treat shingles (caused by herpes zoster) and cold sores around the mouth. Valacyclovir is also used to treat outbreaks of genital herpes. In people with frequent outbreaks, this medication is used to reduce the number of future episodes. Valacyclovir is an antiviral drug. It stops the growth of certain viruses. However, it is not a cure for these infections. The viruses that cause these infections continue to live in the body even between outbreaks. Valacyclovir decreases the severity and length of these outbreaks. It helps the sores heal faster, keeps new sores from forming, and decreases pain/itching. This medication may also help reduce how long pain remains after the sores heal.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like JESSICA LYNN LEVATINO M.D. provides transparency into local medical care patterns within Stanford, CA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Family Medicine** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.